C1436532||HIF2
C0279702||Clear Cell Renal Cell Carcinoma
C1566585||von Hippel-Lindau tumor-suppressor protein
C1566585||pVHL
C0243095||signature "truncal" event
C0279702||clear cell renal cell carcinoma
C1378703||kidney cancer
C1566585||pVHL
C0077678||ubiquitin ligase
C0599220||α subunit
C1528322||hypoxia-inducible factor (HIF) transcription factor
C0008972||studies
C1514542||deregulation
C1528322||hypoxia-inducible factor
C1436532||HIF2
C1566585||pVHL
C1378703||renal carcinogenesis
C0538487||HIF2α
C0041740||University of Texas Southwestern
C1328819||small molecule
C0243076||HIF2α antagonists
C3896783||PT2385
C0243076||PT2399
C0815266||Peloton Therapeutics
C1323327||dimerization
C0538487||HIF2α
C1506870||protein ARNT1
C1512773||inhibit clear cell renal cell carcinoma growth
C1514292||preclinical models
C3896783||PT2385
C0442592||clinic
C1254351||such compounds
C3658200||clustered regularly interspaced short palindromic repeat
C3658200||clustered regularly interspaced short palindromic repeat
C4277689||gene editing approaches
C0279702||clear cell renal carcinomas
C0520484||xenografts
C1436532||HIF2
C0041366||predictive biomarkers
C1254351||such agents
C0442592||clinic